Haemonetics Corporation updated revenue guidance for the fiscal year 2024. For the year, the company expects GAAP total reported revenue growth to be between 10% to 12% against previous guidance of total reported revenue growth to be between 8% to 10% and total organic revenue growth to be between 10% to 12% against previous guidance of total organic revenue growth to be between 8% to 10%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.61 USD | -2.03% | +1.82% | +0.12% |
May. 29 | Haemonetics Insider Sold Shares Worth $1,144,208, According to a Recent SEC Filing | MT |
May. 29 | Haemonetics Insider Sold Shares Worth $775,253, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.12% | 4.36B | |
-2.26% | 187B | |
+2.05% | 110B | |
-1.31% | 69.54B | |
+14.65% | 46.37B | |
-6.69% | 46.05B | |
+7.97% | 42.54B | |
+18.60% | 30.72B | |
-6.87% | 23.32B | |
-10.63% | 22.92B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024